Anavex Life Sciences Corp. (AVXL)
NASDAQ: AVXL · Real-Time Price · USD
4.060
-0.140 (-3.33%)
At close: Mar 20, 2026, 4:00 PM EDT
4.059
-0.001 (-0.02%)
After-hours: Mar 20, 2026, 7:49 PM EDT

Anavex Life Sciences Cash Flow Statement

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Net Income
-39.95-46.38-43-47.51-47.98-37.91
Stock-Based Compensation
10.611.559.4416.3718.388.23
Other Adjustments
---0.85--
Changes in Accounts Payable
-1.93-5.385.310.5-0.910.75
Changes in Accrued Expenses
-4.81-0.94-2.461.350.332.3
Changes in Unearned Revenue
-0.04-0.04-0.080.47-0.44
Changes in Other Operating Activities
2.032.14-0.020.195.95-4.2
Operating Cash Flow
-34.08-39.04-30.81-27.79-24.24-30.38
Issuance of Common Stock
38.5612.1411.9829.6522158.79
Net Common Stock Issued (Repurchased)
38.5612.1411.9829.6522158.79
Other Financing Activities
-0.45-2.71---0.71-5.55
Financing Cash Flow
45.059.4311.9829.6521.29153.24
Net Cash Flow
10.97-29.61-18.841.87-2.95122.86
Free Cash Flow
-34.08-39.04-30.81-27.79-24.24-30.38
Free Cash Flow Per Share
-0.39-0.46-0.37-0.35-0.32-0.44
Levered Free Cash Flow
-10.42-50.59-40.25-45-42.26-38.35
Unlevered Free Cash Flow
-49.62-55.62-50.13-53.26-45.63-42.71
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q